View all text of Subpart B [§ 892.1000 - 892.2100]

§ 892.2085 - Radiology software for referral of findings related to fibrotic lung disease.

(a) Identification. Radiology software for referral of findings related to fibrotic lung disease is a prescription image processing device that analyzes computed tomography images to suggest the presence of disease or of an imaging finding suggestive of disease. The output of this device is intended to be used as adjunctive information as part of a referral pathway in the overall diagnostic assessment process.

(b) Classification. Class II (special controls). The special controls for this device are:

(1) Data obtained from premarket clinical performance validation testing and postmarket surveillance acquired under anticipated conditions of use must demonstrate that the device performs as intended when used to analyze data from the intended patient population, unless FDA determines based on the totality of the information provided for premarket review that data from postmarket surveillance is not required. The following must be met:

(i) Validation report(s) must include a detailed description of the data, criteria, and methods used to define the reference standard that were used to evaluate device performance. The reference standard used in the clinical validation must be justified for the condition named in the device's indications for use.

(ii) The performance of the device must be compared to an appropriate clinical control, (e.g., the performance or agreement of clinicians performing the same task).

(iii) The performance assessment must be based on pre-specified diagnostic accuracy measures (e.g., receiver operator characteristic plot, sensitivity, specificity, positive/negative predictive values, diagnostic likelihood ratios).

(iv) Test datasets must contain a sufficient number of cases from important cohorts (i.e., subsets defined by clinically relevant demographics, confounders, effect modifiers, concomitant diseases, challenging cases such as early disease, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals of the device for these individual subsets can be characterized for the intended-use population and imaging equipment.

(2) Software verification, validation, and hazard analysis must be performed. Software documentation must include a detailed technical description of all image analysis algorithms, including the model inputs and outputs, each major component or block, and any model limitations.

(3) Labeling must include:

(i) A detailed description of the clinical environment and context of use, including information on interpretation of outputs within the intended workflow;

(ii) A detailed description of compatible imaging hardware and imaging protocols;

(iii) A detailed summary of the performance testing for each device output, including test methods, dataset characteristics, testing environment, results (with confidence intervals), and a summary of sub-analyses on case distributions stratified by relevant confounders;

(iv) According to the timeframe specified in any postmarket surveillance protocol approved by FDA to satisfy the requirements in paragraph (b)(1) of this section, a detailed summary of the postmarket surveillance data must be provided, including updates to the labeling to accurately reflect device performance based upon data collected during the postmarket surveillance experience; and

(v) Limiting statements that indicate:

(A) A description of situations in which the device may fail or may not operate at its expected performance level (e.g., the impact of poor image quality on device performance or degraded performance in certain subpopulations), as applicable, including any limitations in the dataset used to train, tune, and test the algorithm during device development;

(B) A discussion of what the device detects in the context of diagnosing fibrotic lung disease; and

(C) A warning that users should use the device in conjunction with other clinical and diagnostic findings, including information obtained by alternative methods and clinical evaluation, as appropriate.

[91 FR 68469, Oct. 30, 2026]